Study to investigate the effect of the A1 agonist capadenoson on ventricular HR [heart rate] in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days.

Trial Profile

Study to investigate the effect of the A1 agonist capadenoson on ventricular HR [heart rate] in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Capadenoson (Primary) ; Metoprolol
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-003619-30).
    • 14 Apr 2010 Actual number of patients added to 25 as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Actual end date added to 1 Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top